ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2025

Capturing the Additional Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists Beyond the Control of Traditional Risk Factors in People With Diabetes.

Shu Niu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.